Spyre Therapeutics Inc SYRE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $83.58
- Day Range
- $81.70–84.93
- 52-Week Range
- $13.93–84.93
- Bid/Ask
- $83.40 / $83.47
- Shares Outstanding
- 86.84M
- Market Cap
- $7.24B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 112
- Website
- https://www.spyre.com
Valuation
|
Metric
|
SYRE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 12.37 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SYRE
Financial Strength
|
Metric
|
SYRE
|
|---|---|
Quick Ratio | 8.71 |
Current Ratio | 8.97 |
Interest Coverage | — |
Quick Ratio
SYRE
Profitability
|
Metric
|
SYRE
|
|---|---|
Return on Assets (Normalized) | −28.19% |
Return on Equity (Normalized) | −44.46% |
Return on Invested Capital (Normalized) | −36.56% |
Return on Assets
SYRE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Nsrmrwlrc | Ltpsrs | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nyqwbnnht | Chlnvg | $64B | |||
| argenx SE ADR
ARGX
| Nbdtzqkgn | Bglg | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kggszyg | Ntnkdy | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Hkwvfbxym | Gwtsy | $24B | |||
| BioNTech SE ADR
BNTX
| Lhvdfmqh | Wrn | $23B | |||
| Incyte Corp
INCY
| Ryvhsdh | Fxk | $22B | |||
| Moderna Inc
MRNA
| Qsxtgrpv | Rppj | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Brxmsfwv | Rxrh | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Tnztdjwr | Yzd | $13B |
United States